Heparin Affinity Purification of CVB1 for High-Throughput Recovery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for purifying Coxsackievirus B1 (CVB1) are inefficient, with low throughput, long operation times, and low virus purity and recovery rates, making them unsuitable for commercial scale-up.
Innovation Solution
A method utilizing heparin affinity chromatography, combined with optional size exclusion and adsorption chromatography, to purify CVB1, involving steps like sample adjustment, binding, dissociation, and collection, using media like Capto Heparin, UniGel-65 Heparin, or Cellufine Sulfate, with specific conductance and pH conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If ultracentrifugation and density gradient centrifugation are used to purify CVB1, then virus purity can be improved, but productivity decreases due to low throughput and long operation time
Solution Approach 1:
The patent replaces mechanical centrifugation systems with a chromatography-based purification system. The heparin affinity chromatography column provides a stationary phase that selectively binds CVB1 viruses through specific interactions, enabling purification without requiring high-speed centrifugation. This substitution allows for higher throughput and shorter operation times while maintaining virus purity.
Solution Approach 2:
The patent utilizes changes in solution parameters (flow rate, buffer composition, pH, ionic strength) to control the binding and elution of CVB1 from the heparin affinity column. By optimizing these parameters, the system achieves high purity separation with improved productivity, as the chromatography process can be scaled and automated more easily than centrifugation methods.
2Manufacturing precision
If ultracentrifugation and density gradient centrifugation are used to purify CVB1, then virus purity can be improved, but operation time increases
Solution Approach 1:
The patent replaces time-consuming mechanical centrifugation steps with a chromatography-based approach that uses selective binding mechanisms. The heparin affinity column allows CVB1 to be captured and purified through fluid flow dynamics rather than mechanical separation, significantly reducing the time required for purification while maintaining high virus purity.
3Manufacturing precision
If conventional purification methods are used, then virus purity can be improved, but recovery rate decreases
Solution Approach 1:
The patent introduces heparin affinity chromatography as an intermediary purification step between virus production and final formulation. The heparin column acts as a selective mediator that captures CVB1 viruses while allowing impurities to pass through, thereby improving both purity and recovery rate simultaneously by providing a gentle, selective separation mechanism.
4Ease of manufacture
If purification process is simplified, then ease of manufacture improves, but purification effectiveness may worsen
Solution Approach 1:
The patent replaces complex multi-step mechanical purification procedures with a single chromatography column system. The heparin affinity column integrates multiple purification functions (capture, separation, concentration) into one platform, simplifying the manufacturing process while maintaining high purification effectiveness through the selective binding properties of heparin for CVB1 viruses.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Achieves high CVB1 infection titer recovery rates, effective impurity removal (over 99% HCP and HCD), and simplifies the purification process, enabling large-scale production suitable for industrial applications.
Implementation Method 1
contacting the sample with a heparin affinity medium
Implementation Method 2
CVB1 in the sample bind the heparin affinity chromatography medium to form a complex
Implementation Method 3
subjecting the complex to dissociation
Data Source
AI summary
The present invention relates to a method for separating and purifying CVB1, and particularly, relates to a method for purifying CVB1 virus by using a heparin affinity medium.